AIA Group Ltd Has $425,000 Stock Position in Boston Scientific Co. (NYSE:BSX)

AIA Group Ltd lessened its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 72.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,207 shares of the medical equipment provider’s stock after selling 16,110 shares during the quarter. AIA Group Ltd’s holdings in Boston Scientific were worth $425,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in BSX. Bruce G. Allen Investments LLC bought a new position in Boston Scientific during the 4th quarter worth about $28,000. RiverPark Advisors LLC bought a new position in Boston Scientific during the 1st quarter worth about $30,000. Northwest Investment Counselors LLC bought a new position in Boston Scientific during the 1st quarter worth about $31,000. Sachetta LLC bought a new position in Boston Scientific during the 4th quarter worth about $32,000. Finally, Frazier Financial Advisors LLC bought a new position in shares of Boston Scientific in the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $77.30, for a total value of $539,785.90. Following the completion of the sale, the executive vice president now owns 42,908 shares in the company, valued at approximately $3,316,788.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Edward J. Ludwig sold 9,818 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $73.29, for a total transaction of $719,561.22. Following the completion of the sale, the director now owns 41,374 shares in the company, valued at approximately $3,032,300.46. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $77.30, for a total transaction of $539,785.90. Following the sale, the executive vice president now owns 42,908 shares of the company’s stock, valued at approximately $3,316,788.40. The disclosure for this sale can be found here. Insiders sold a total of 72,259 shares of company stock valued at $5,344,014 over the last three months. Corporate insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. raised their target price on shares of Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. StockNews.com upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Friday. Needham & Company LLC restated a “buy” rating and set a $82.00 price objective on shares of Boston Scientific in a research report on Tuesday, June 18th. Mizuho raised their price objective on shares of Boston Scientific from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, May 15th. Finally, Wells Fargo & Company raised their price objective on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Two analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $78.29.

Boston Scientific Trading Up 1.0 %

BSX stock traded up $0.80 during midday trading on Friday, hitting $77.69. The stock had a trading volume of 4,430,837 shares, compared to its average volume of 6,161,429. The firm has a market cap of $113.98 billion, a P/E ratio of 65.29, a price-to-earnings-growth ratio of 2.65 and a beta of 0.78. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $77.99. The business has a fifty day moving average price of $75.81 and a two-hundred day moving average price of $68.96.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.05. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. The firm had revenue of $3.86 billion for the quarter, compared to analyst estimates of $3.68 billion. On average, sell-side analysts predict that Boston Scientific Co. will post 2.32 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.